Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

PHASE3CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

June 10, 2022

Study Completion Date

January 13, 2023

Conditions
Gastroenteropancreatic Neuroendocrine Tumor
Interventions
DRUG

Lanreotide autogel

Administered as deep subcutaneous (SC) injections

Trial Locations (14)

100021

Cancer Hospital Chinese Academy of Sciences, Beijing

100142

Beijing Cancer Hospital, Beijing

100191

Peking University Third Hospital, Beijing

150081

Harbin Medical University Cancer Hospital, Harbin

200032

Zhongshan Hospital Affiliated to Fudan University, Shanghai

200433

Fudan University Shanghai Cancer Centre, Shanghai

250012

Qilu Hospital Of Shandong University, Jinan

310009

The second affiliated hospital of Zhejiang University School of Medicine, Hangzhou

310058

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510080

The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou

610041

West China Hospital of Sichuan University, Chengdu

710061

The First Affiliated Hospital Of Xi'an Jiaotong University, Xi’an

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY